Establishment of an Adeno-associated Virus-mediated, Locally Inducible Mouse Model of SS18–SSX2-driven Synovial Sarcoma
This study establishes a locally inducible mouse model of synovial sarcoma by demonstrating that optimized, low-dose intramuscular delivery of AAV9-CMV-iCre successfully activates a conditional SS18–SSX2 allele to induce proliferative lesions in adult mice while minimizing off-target effects and mortality.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Cancer often begins with a single mistake in a cell's genetic code, a typo that tells the cell to grow when it should stop. In a specific and aggressive type of soft tissue cancer called synovial sarcoma, this mistake is a known event: two separate genes, which normally sit far apart on different chromosomes, accidentally swap places and fuse together. This fusion creates a new, hybrid gene that acts as a relentless engine, driving the cell to divide uncontrollably. Because this genetic signature is so consistent, scientists have long used it to identify the disease in patients. However, understanding how this single genetic error leads to a full-blown tumor has been difficult. Previous attempts to study this in mice relied on breeding animals that carried the faulty gene, but these models were limited because the error was turned on in specific cell types from the very beginning of the animal's life. This made it hard to see how the disease might start in different tissues or to test new ways of triggering the cancer in adult animals.
To overcome these limitations, researchers at the University of Tsukuba set out to build a more flexible tool. They wanted to create a mouse model where the cancer-driving gene was present but silent, waiting to be switched on only when and where the scientists decided. They engineered a new line of mice carrying the human version of the fused gene, but they placed a genetic "stop sign" in front of it. This stop sign would only be removed if a specific enzyme, called Cre, was introduced into the cell. The team then turned their attention to a virus known as adeno-associated virus, or AAV, which is commonly used to deliver genetic material into cells. They loaded this virus with the instructions to make the Cre enzyme and injected it directly into the leg muscles of their specially bred mice. The goal was to see if this viral delivery could successfully switch on the cancer gene in adult tissue, causing tumors to form without the need for complex breeding or pre-defined cell types.
The researchers first tested a high dose of the virus, injecting one hundred billion viral particles into the leg muscles of the mice. The results were sobering. The high dose proved too toxic; five out of seven mice died from respiratory failure within a few months. In the one mouse that survived long enough for a full examination, the virus had traveled far beyond the injection site. Instead of finding tumors in the legs, the researchers discovered a growing mass in the brain. This brain tumor contained cells that had successfully switched on the cancer gene, proving that the virus could deliver its payload, but also showing that at this high dose, the virus spread too widely and caused fatal side effects. The team realized that to study the disease safely, they needed to dial back the intensity of their delivery.
They repeated the experiment with a much smaller dose, injecting ten billion viral particles into the same leg muscles. This time, the mice tolerated the treatment well, with no signs of respiratory distress. The outcome was strikingly different. In four out of the five mice, distinct lumps began to form in the legs. These were not just random swellings; microscopic examination revealed them to be dense clusters of rapidly dividing cells. Crucially, the cancer gene was active inside these cells, and many of them were in the process of dividing, confirming that the viral injection had successfully triggered the disease. Even more interesting, tumors appeared not only in the leg that received the injection but also in the opposite, untreated leg. This suggested that even at the lower dose, a small amount of the virus had circulated through the body and reached the other side, yet the tumors remained localized to the muscle tissue rather than spreading to vital organs like the brain.
The study demonstrates that it is possible to induce this specific type of cancer in adult mice simply by injecting a virus into a muscle, without needing to breed animals with pre-existing genetic defects. The researchers confirmed that the tumors contained the exact genetic marker found in human synovial sarcoma and that the cells were actively growing. While the method was not perfectly confined to the injection site, as some virus did reach the other leg, the lower dose prevented the severe toxicity and widespread organ damage seen in the first trial. This approach offers a new way to study how synovial sarcoma develops in adult tissue and provides a platform for testing treatments in a setting that closely mimics the genetic reality of the human disease. By showing that a viral vector can reliably switch on a cancer gene in specific tissues, the work opens a path for future research into how these tumors interact with their environment and how they might be stopped.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.